HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 11, November 2017 – Paediatric Illnesses       » Breakthrough new rice variety announced in Northern China       » Ebola vaccine approved in China       » Study reveals anti-cancer properties of a fungus used in traditional medicine       » Chinese scientists create genetically modified low-fat pigs       » China, Brazil and Russia are riskiest markets for compliance and regulation       » Why are Korean eggs salmonella-free?      
BIOBOARD - AUSTRALIA
Fellowship supports search for new disease treatments

La Trobe University and leading Australian biotech company AdAlta have received new funding to identify and develop potential treatments for a range of human diseases using the company’s novel class of drugs, known as i-bodies.

La Trobe University’s Dr Chris Hosking has been awarded a Science and Industry Endowment Fund (SIEF) Business Fellowship worth $427,000 ($210,000 from the CSIRO), further strengthening the collaboration between La Trobe University and AdAlta.

The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology, while also helping to grow into larger and more profitable organisations.

Furthermore, the program provides practical industry experience for early career researchers.

The SIEF Fellowship grant will support Dr Hosking’s work with AdAlta’s Chief Scientific Officer, Professor Mick Foley, at the La Trobe Institute for Molecular Science.

“Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets, such as complex signalling proteins called GPCRs,” Professor Foley said.

“Chris is an excellent candidate for the Fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team.”

La Trobe Pro Vice Chancellor Industry and Engagement, Dr Daniel Grant, congratulated Dr Hosking.

“La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies,” Dr Grant said. “We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties.”

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treatment of a wide range of human diseases.

AdAlta pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein.

Source: La Trobe University

Click here for the complete issue.

NEWS CRUNCH  
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
news Novogen becomes Kazia Therapeutics
news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy